ストックスクリーナーアプリを入手
39.78
3.30%
1.1751
Harrow Inc (HROW) 最新ニュース
Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat
These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus
Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - GlobeNewswire
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis
Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis
With Harrow Stock Sliding, Have You Assessed The Risk? - Trefis
HROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - ADVFN Ltd
Harrow (HROW) Projects Strong Growth with Expanding Ophthalmic P - GuruFocus
Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan
Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha
Harrow Q4 Earnings Call Highlights - Yahoo Finance
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews
HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView
Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan
Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use - simplywall.st
Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down - Nasdaq
Harrow Reports Substantial Q4 and Full-Year 2025 Revenue Growth - VisionMonday.com
Harrow Q4 2025 Earnings Report: Revenue $89.1M, Net Income $6.6MNews and Statistics - IndexBox
Harrow Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Harrow (HROW) Misses Q4 Earnings Estimates - Yahoo Finance
Harrow Health (HROW) Q4 Earnings Miss Despite Revenue Beat - GuruFocus
Harrow (HROW) Sets Ambitious Financial Targets for FY26 - GuruFocus
Harrow Reports Q4 Earnings - National Today
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance - Bitget
Harrow Health Posts Record 2025 Results, Sets 2026 Outlook - TipRanks
Harrow: Q4 Earnings Snapshot - Citizen Tribune
Harrow Health Stock Slides After 2026 Outlook Shock - TipRanks
Harrow Inc. (HROW) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Harrow : Q4-2025 Letter to Stockholders - marketscreener.com
Harrow Earnings Review: Q4 Summary - Benzinga
HROW: 2025 revenue surged 36% to $272.3M, net loss narrowed, and branded sales led growth - TradingView
Harrow 10-K: $272.3M Revenue, $(0.14) EPS on improved net loss - TradingView
[10-K] HARROW, INC. Files Annual Report | HROW SEC FilingForm 10-K - Stock Titan
Earnings Flash (HROW) Harrow Posts Q4 EPS $0.17, vs. FactSet Est of $0.37 - marketscreener.com
Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook - Stock Titan
Why Is Eye-Disease-Focused Harrow Stock Falling Today? - Bitget
Earnings Flash (HROW) Harrow, Inc. Reports Q4 Revenue $89.1M, vs. FactSet Est of $90.0M - marketscreener.com
All eyes on Harrow Health earnings amid VEVYE coverage win - Investing.com
Harrow, Inc. $HROW Shares Sold by Royce & Associates LP - MarketBeat
88,855 Shares in Harrow, Inc. $HROW Bought by Lumbard & Kellner LLC - MarketBeat
Harrow: Q4 Financial Overview - Bitget
Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance
HROW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Harrow Health (HROW) Set to Announce Q4 Earnings - GuruFocus
A Preview Of Harrow's Earnings - Benzinga
Harrow’s PharmaPack Aims To Reshape Cataract Surgery Prescribing And Access - simplywall.st
Harrow Bets On AI And PharmaPack To Reshape Ophthalmic Distribution - Yahoo Finance
Is It Too Late To Look At Harrow Health (HROW) After Its 1-Year 90% Surge? - simplywall.st
Harrow, Inc. (HROW) Investor Outlook: A Potential 37% Upside in the Eyecare Pharmaceuticals Sector - DirectorsTalk Interviews
Harrow (HROW) Is Up 8.1% After Launching PharmaPack Cash-Pay Ophthalmic Kits For Cataract Surgery - simplywall.st
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
FOMO Trade: Does Harrow Inc have strong EBITDA marginsMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Will Harrow Inc. stock attract more institutional investorsMarket Growth Report & Expert Verified Movement Alerts - mfd.ru
Harrow to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 - The Manila Times
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - markets.businessinsider.com
Harrow, Inc. Announces Cash-Pay Direct-To-Prescriber Pharmapack?? Kits - marketscreener.com
0.10%
0.66%
大文字化:
|
ボリューム (24 時間):